xPedite: A Study to Expedite DIPG and DMG Research

Description

This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external, contemporary or historical control arm for future therapeutic development programs of drugs, devices, or biologic interventions in DMG or DIPG.

Conditions

Oncology, DIPG, DMG

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external, contemporary or historical control arm for future therapeutic development programs of drugs, devices, or biologic interventions in DMG or DIPG.

A Retrospective and Prospective Observational Sub-Study for Diffuse Midline Glioma and Diffuse Intrinsic Pontine Glioma

xPedite: A Study to Expedite DIPG and DMG Research

Condition
Oncology
Intervention / Treatment

-

Contacts and Locations

Los Altos

xCures, Inc., Los Altos, California, United States, 94022

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Diagnosis of diffuse midline glioma according to the WHO 2021 Classification of Tumors of the Central Nervous System diagnostic criteria including diffuse intrinsic pontine glioma (DIPG). In the absence of a pathologically confirmed diagnosis, a grade IV glioma involving the thalamus, hypothalamus, brainstem, cerebellum, midbrain, or spinal cord, or with a pontine epicenter and diffuse involvement of the pons.
  • 2. Patients with any performance status, comorbidity or disease severity are eligible
  • 3. Patients or their legally-authorized representative must be willing and able to provide electronic, informed consent (and assent, if applicable)
  • 4. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088).
  • 5. Patients must be a resident of or receiving care within the United States or US territories.
  • 1. Patient or legally-authorized representative is unable to provide informed consent.
  • 2. Patient or caregiver is unable to complete the PRO and ClinRO by an electronic platform.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

xCures,

Mark Shapiro, PhD, PRINCIPAL_INVESTIGATOR, xCures

Study Record Dates

2027-01